Pmv Pharmaceuticals, INC Form 4 insider transactions

Director Laurie Stelzer was granted 42,000 stock options in PMV Pharmaceuticals, Inc. as part of an equity compensation plan.

Director Arnold J. Levine was granted 42,000 stock options in PMV Pharmaceuticals, Inc. on June 4, 2026.

Director Carol Giltner Gallagher received a stock option grant and subsequently transferred the holdings to a revocable trust.

Director Kirsten Flowers was granted 42,000 stock options in PMV Pharmaceuticals, Inc. as part of an equity incentive.

Director Charles M. Baum was granted 42,000 stock options in PMV Pharmaceuticals, Inc. as part of a standard equity incentive.

PMV Pharmaceuticals President and CEO, David Henry Mack, exercised options to acquire 220,643 shares of common stock at $1.37 per share.

OrbiMed Advisors and OrbiMed Capital GP V LLC reported the sale of 1,000,000 shares of PMV Pharmaceuticals, Inc. common stock at $1.52 per share.

OrbiMed Advisors, a 10% owner and director of PMV Pharmaceuticals, reported a pre-planned sale of 500,000 common shares at $1.80 per share.

Robert Ticktin, General Counsel and COO of PMV Pharmaceuticals, Inc., sold 23,151 shares of common stock to satisfy tax obligations related to restricted stock unit vesting.

Deepika Jalota, Chief Development Officer of PMV Pharmaceuticals, sold 33,065 shares of common stock on July 1, 2025, to cover tax obligations related to restricted stock unit vesting.

PMV Pharmaceuticals' Chief Financial Officer, Michael Carulli, sold 28,249 shares of common stock for $1.0647 per share to satisfy tax obligations related to the vesting of restricted stock units.

PMV Pharmaceuticals' President and CEO, David Henry Mack, sold 58,411 shares of common stock to cover tax obligations related to restricted stock unit vesting, while retaining substantial direct and indirect ownership.

PMV Pharmaceuticals, Inc. Director Laurie Stelzer acquired 33,500 stock options with an exercise price of $0.95, which will vest by June 2026 or the next annual stockholders' meeting.

PMV Pharmaceuticals, Inc. Director Arnold J. Levine has acquired 33,500 stock options with an exercise price of $0.95, signaling potential long-term confidence in the company's future.

PMV Pharmaceuticals, Inc. director Richard A. Heyman was granted 33,500 stock options with an exercise price of $0.95, aligning his interests with future company performance.

Carol Giltner Gallagher, a Director at PMV Pharmaceuticals, Inc., has been granted 33,500 stock options with an exercise price of $0.95, vesting by June 2026 or the next annual meeting.

Kirsten Flowers, a Director at PMV Pharmaceuticals, Inc., was granted 33,500 stock options with an exercise price of $0.95, vesting on the earlier of June 5, 2026, or the next annual meeting of stockholders.

Charles M. Baum, a Director at PMV Pharmaceuticals, Inc., acquired 33,500 stock options with an exercise price of $0.95, vesting by June 2026 or the next annual meeting.

Michael Carulli, CFO of PMV Pharmaceuticals, acquired 265,000 employee stock options on March 3, 2025, according to a Form 4 filing.

Deepika Jalota, Chief Development Officer of PMV Pharmaceuticals, reports the acquisition of stock options and shares.

David Henry Mack, President and CEO of PMV Pharmaceuticals, reports the acquisition of stock options and updates to his beneficial ownership of company stock.

David Henry Mack, President and CEO of PMV Pharmaceuticals, reports exercising stock options and subsequent changes in beneficial ownership of company stock.

Deepika Jalota, Chief Development Officer of PMV Pharmaceuticals, participated in an option exchange program, resulting in the cancellation and replacement of several employee stock options.

Chief Financial Officer of PMV Pharmaceuticals, Michael Carulli, participated in an option exchange program, resulting in the cancellation of existing stock options and the grant of new options with a lower exercise price.

CEO David Henry Mack exchanged existing stock options for new options with a lower exercise price as part of PMV Pharmaceuticals' option exchange program.

Deepika Jalota, Chief Development Officer of PMV Pharmaceuticals, sold shares of common stock to cover tax obligations related to vesting of restricted stock units.

Michael Carulli, CFO of PMV Pharmaceuticals, sold 2,891 shares of common stock on September 11, 2024, to cover tax obligations related to vesting restricted stock units.

Laurie Stelzer, a director at PMV Pharmaceuticals, acquired stock options for 67,500 shares at an exercise price of $1.65 on June 6, 2024, according to a Form 4 filing.

Director Arnold Levine reported the acquisition of stock options in PMV Pharmaceuticals, Inc.

Director Richard A. Heyman acquired 67,500 stock options in PMV Pharmaceuticals, Inc. on June 6, 2024, according to a Form 4 filing.